Non-Hormonal Pharmacotherapies for Benign Prostatic Hyperplasia: The Role of Beta-Sitosterol Monotherapy

Al-Mosawi AJ

Published on: 2025-09-09

Abstract

Many medications have been used in the treatment of benign enlargement of the prostate during the 1960s, 1970s, and 1980s, including progestational agents, amino acids, spironolactone, candicidin, nystatin, flutamide, bromocriptine, alpha-adrenergic blockers, Serenoa repens (Saw palmetto extracts), and mepartricin. 

Finasteride and dutasteride are 5-alpha reductase inhibitors decrease levels of dihydrotestosterone, which contributes to prostate enlargement, have been increasingly used in the treatment of benign prostatic hyperplasia.

There is some evidence suggesting that non-hormonal therapies (i.e., medication that do not directly affect male hormones like testosterone or dihydrotestosterone) can reduce prostate volume, particularly in the context of benign prostatic hyperplasia.

Beta-sitosterol, a plant sterol has emerged as a promising natural therapeutic option for benign prostatic hyperplasia. This paper explores the efficacy of beta-sitosterol monotherapy in the treatment of benign prostatic hyperplasia, with a focus on its potential to reduce prostate volume and alleviate symptoms.